Perspective Therapeutics (NASDAQ:CATX) Given Average Recommendation of “Buy” by Analysts

Perspective Therapeutics (NASDAQ:CATX) has been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued a report on the stock in the last year is $11.8571.

A number of analysts have recently issued reports on the company. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Friday, January 30th. BTIG Research reiterated a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 13th. UBS Group cut their price target on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, November 21st. B. Riley Financial lowered their price objective on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, Piper Sandler started coverage on shares of Perspective Therapeutics in a report on Thursday. They set an “overweight” rating and a $16.00 price objective for the company.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $28,000. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the fourth quarter worth approximately $31,000. AXQ Capital LP grew its position in Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares during the last quarter. Engineers Gate Manager LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth approximately $35,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth approximately $42,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Stock Down 0.9%

NASDAQ:CATX opened at $5.60 on Tuesday. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $6.16. The company’s fifty day simple moving average is $3.48. The company has a market capitalization of $416.29 million, a price-to-earnings ratio of -6.22 and a beta of 1.75.

About Perspective Therapeutics

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.